Transforming Growth Factor-β Modulates Cancer Stem Cell Traits on CD44 Subpopulations in Hepatocellular Carcinoma

Overview

Journal J Cell Biochem

Specialties Biochemistry
Cell Biology

Date 2025 Feb 13

PMID 39943801

Authors

Mario Alejandro Aguilar-Chaparro

Sonia Andrea Rivera-Pineda

Hury Viridiana Hernandez-Galdamez

Emmanuel Rios-Castro

Olga Lilia Garibay-Cerdenares

Carolina Pina-Vazquez

Saul Villa-Trevino

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a formidable malignancy, with growing interest in identifying cancer stem cells (CSCs) as potential therapeutic targets. CD44 isoforms have emerged as promising CSC markers in HCC, often associated with epithelial-mesenchymal transition (EMT) induced by transforming growth factor-beta (TGF-β). However, the intricate relationship between CSC traits, CD44 isoforms, and TGF-β effects on CD44 subpopulations in HCC remains unclear. This study aimed to clarify how TGF-β influences proteomic changes and CSC traits in subpopulations expressing standard CD44 isoform (CD44std) and CD44 variant 9 (CD44v9). Treating SNU-423 cells with TGF-β lead to notable morphological changes, resembling a spindle-like phenotype, along with reductions in CD44v9+ subpopulations and differential CD44std expression. Proteomic analysis highlighted significant alterations in signaling pathways, particularly the mitogen-activated protein kinase (MAPK) pathway. Validation experiments demonstrated upregulation in CD44std cells and downregulation in CD44v9 cells post-TGF-β treatment. Furthermore, TGF-β exerted regulatory influence over Sox2 and Nanog expression, resulting in increased colony and spheroid formation in CD44std cells but decreased capabilities in CD44v9 cells. TGF-β also enhanced the migratory and invasive properties of both subpopulations through EMT, alongside increased adhesive abilities in CD44v9 cells. These findings illuminate the dynamic interplay between TGF-β and CD44std/CD44v9 subpopulations, emphasizing the role of MAPK signaling and modulation of CSC traits. This research contributes to understanding the dynamic interplay between CD44 isoforms and TGF-β in HCC.

References

Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H . CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 2012; 72(13):3414-23. DOI: 10.1158/0008-5472.CAN-12-0299. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Zhang H, Dou K . PCBP1 is an important mediator of TGF-β-induced epithelial to mesenchymal transition in gall bladder cancer cell line GBC-SD. Mol Biol Rep. 2014; 41(8):5519-24. DOI: 10.1007/s11033-014-3428-7. View

Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H . The expression levels of CD44v6 are correlated with the invasiveness of hepatocellular carcinoma in vitro, but do not appear to be clinically significant. Oncol Lett. 2012; 3(5):1047-1051. PMC: 3389621. DOI: 10.3892/ol.2012.611. View

Zhou J, Du Y, Lu Y, Luan B, Xu C, Yu Y . CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1. Front Oncol. 2019; 9:802. PMC: 6712994. DOI: 10.3389/fonc.2019.00802. View

Azevedo R, Gaiteiro C, Peixoto A, Relvas-Santos M, Lima L, Santos L . CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications. Clin Proteomics. 2018; 15:22. PMC: 6020424. DOI: 10.1186/s12014-018-9198-9. View

Moon H, Ro S . MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers (Basel). 2021; 13(12). PMC: 8234271. DOI: 10.3390/cancers13123026. View

Aguilar-Chaparro M, Rivera-Pineda S, Hernandez-Galdamez H, Pina-Vazquez C, Villa-Trevino S . The CD44std and CD44v9 subpopulations in non-tumorigenic invasive SNU-423 cells present different features of cancer stem cells. Stem Cell Res. 2023; 72:103222. DOI: 10.1016/j.scr.2023.103222. View

Guo Y, Pan W, Liu S, Shen Z, Xu Y, Hu L . ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020; 19(3):1997-2007. PMC: 7027163. DOI: 10.3892/etm.2020.8454. View

10.

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

11.

Chen Q, Gu M, Cai Z, Zhao H, Sun S, Liu C . TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44. Cell Mol Life Sci. 2020; 78(3):949-962. PMC: 11072728. DOI: 10.1007/s00018-020-03544-5. View

12.

Sugiura R, Satoh R, Takasaki T . ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer. Cells. 2021; 10(10). PMC: 8533760. DOI: 10.3390/cells10102509. View

13.

Evanko S, Potter-Perigo S, Petty L, Workman G, Wight T . Hyaluronan Controls the Deposition of Fibronectin and Collagen and Modulates TGF-β1 Induction of Lung Myofibroblasts. Matrix Biol. 2015; 42:74-92. PMC: 4524654. DOI: 10.1016/j.matbio.2014.12.001. View

14.

Park N, Cha J, Jang J, Bae S, Jang B, Kim J . Synergistic effects of CD44 and TGF-β1 through AKT/GSK-3β/β-catenin signaling during epithelial-mesenchymal transition in liver cancer cells. Biochem Biophys Res Commun. 2016; 477(4):568-574. DOI: 10.1016/j.bbrc.2016.06.077. View

15.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

16.

Wang L, Zuo X, Xie K, Wei D . The Role of CD44 and Cancer Stem Cells. Methods Mol Biol. 2017; 1692:31-42. DOI: 10.1007/978-1-4939-7401-6_3. View

17.

Mima K, Hayashi H, Imai K, Kuroki H, Nakagawa S, Okabe H . High CD44s expression is associated with the EMT expression profile and intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy. J Hepatobiliary Pancreat Sci. 2012; 20(4):429-34. DOI: 10.1007/s00534-012-0580-0. View

18.

Gao Y, Ruan B, Liu W, Wang J, Yang X, Zhang Z . Knockdown of CD44 inhibits the invasion and metastasis of hepatocellular carcinoma both in vitro and in vivo by reversing epithelial-mesenchymal transition. Oncotarget. 2015; 6(10):7828-37. PMC: 4480719. DOI: 10.18632/oncotarget.3488. View

19.

Sritananuwat P, Sueangoen N, Thummarati P, Islam K, Suthiphongchai T . Blocking ERK1/2 signaling impairs TGF-β1 tumor promoting function but enhances its tumor suppressing role in intrahepatic cholangiocarcinoma cells. Cancer Cell Int. 2017; 17:85. PMC: 5615482. DOI: 10.1186/s12935-017-0454-2. View

20.

Wang D, Lu P, Zhang H, Luo M, Zhang X, Wei X . Correction: Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget. 2021; 12(10):1024-1025. PMC: 8121612. DOI: 10.18632/oncotarget.27791. View